{"id":310,"date":"2020-06-25T08:38:44","date_gmt":"2020-06-25T08:38:44","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=310"},"modified":"2020-06-25T08:40:02","modified_gmt":"2020-06-25T08:40:02","slug":"25-june-2020-tocilizumab-single-dose-helped-reduce-inflammation-oxygen-requirements-vasopressor-support-and-mortality","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/25-june-2020-tocilizumab-single-dose-helped-reduce-inflammation-oxygen-requirements-vasopressor-support-and-mortality\/","title":{"rendered":"(24 June 2020) Tocilizumab- single dose helped reduce inflammation, oxygen requirements, vasopressor support, and mortality"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia<\/p>\n<p class=\"\">https:\/\/academic.oup.com\/cid\/articleabstract\/doi\/10.1093\/cid\/ciaa812\/5861638<\/p>\n<p class=\"\">In a single-center observational study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia clinical and laboratory parameters including oxygen and vasopressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre- and post-tocilizumab treatment were examined. Twenty seven SARS-CoV-2 pneumonia patients received one 400 mg dose of tocilizumab. Significant reductions in temperature and CRP were seen post-tocilizumab. However, four patients did not show rapid CRP declines, of whom three had poorer outcomes. Oxygen and vasopressor requirements diminished over the first week post-tocilizumab. Twenty-two patients required mechanical ventilation; at last follow-up, 16 were extubated. Adverse events and serious adverse events were minimal, but two deaths (7.4%) occurred that were felt unrelated to tocilizumab. Compared to published reports on the morbidity and mortality associated with SARS-CoV-2, tocilizumab appears to offer benefits in reducing inflammation, oxygen requirements, vasopressor support, and mortality.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia https:\/\/academic.oup.com\/cid\/articleabstract\/doi\/10.1093\/cid\/ciaa812\/5861638 In a single-center observational study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia clinical and laboratory parameters including oxygen and vasopressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre-&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/25-june-2020-tocilizumab-single-dose-helped-reduce-inflammation-oxygen-requirements-vasopressor-support-and-mortality\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(24 June 2020) Tocilizumab- single dose helped reduce inflammation, oxygen requirements, vasopressor support, and mortality&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/310"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=310"}],"version-history":[{"count":3,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/310\/revisions"}],"predecessor-version":[{"id":313,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/310\/revisions\/313"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}